Ser681
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser681  -  DBC-1 (human)

Site Information
RsVAsNQsEMEFssL   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 454534

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 13 , 14 , 15 , 16 , 17 , 18 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 )
Disease tissue studied:
breast cancer ( 4 , 8 , 9 , 16 , 17 ) , breast ductal carcinoma ( 8 ) , HER2 positive breast cancer ( 2 ) , luminal A breast cancer ( 2 ) , luminal B breast cancer ( 2 ) , breast cancer, triple negative ( 2 , 8 ) , cervical cancer ( 27 ) , cervical adenocarcinoma ( 27 ) , leukemia ( 3 , 20 , 33 ) , acute myelogenous leukemia ( 20 ) , chronic myelogenous leukemia ( 33 ) , T cell leukemia ( 3 ) , lung cancer ( 6 , 17 , 23 ) , non-small cell lung cancer ( 17 ) , non-small cell lung adenocarcinoma ( 6 ) , lymphoma ( 10 ) , Burkitt's lymphoma ( 10 ) , follicular lymphoma ( 10 ) , mantle cell lymphoma ( 10 ) , ovarian cancer ( 8 ) , melanoma skin cancer ( 5 )
Relevant cell line - cell type - tissue:
293 (epithelial) [ADRB1 (human), no information, overexpresses human beta1-adrenergic (ß1AR- HEK293)] ( 34 ) , 293 (epithelial) [AT1 (human), transfection, AT1R stable transfected HEK293] ( 24 ) , 293 (epithelial) ( 3 , 30 ) , A498 (renal) ( 26 ) , A549 (pulmonary) ( 13 ) , BJAB (B lymphocyte) ( 10 ) , breast ( 2 , 8 ) , BT-20 (breast cell) ( 17 ) , BT-474 (breast cell) ( 4 ) , BT-549 (breast cell) ( 17 ) , Calu 6 (pulmonary) ( 17 ) , CCRF-CEM (T lymphocyte) ( 3 ) , CL1-0 (pulmonary) ( 23 ) , CL1-1 (pulmonary) ( 23 ) , CL1-2 (pulmonary) ( 23 ) , CL1-5 (pulmonary) ( 23 ) , FL-318 (B lymphocyte) ( 10 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 18 ) , Flp-In T-Rex-293 (epithelial) ( 18 ) , GM00130 (B lymphocyte) ( 25 ) , H2009 (pulmonary) ( 17 ) , H2077 (pulmonary) ( 17 ) , H2887 (pulmonary) ( 17 ) , H322M (pulmonary) ( 17 ) , HCC1359 (pulmonary) ( 17 ) , HCC1937 (breast cell) ( 17 ) , HCC2279 (pulmonary) ( 17 ) , HCC366 (pulmonary) ( 17 ) , HCC4006 (pulmonary) ( 17 ) , HCC78 (pulmonary) ( 17 ) , HCC827 (pulmonary) ( 17 ) , HeLa (cervical) ( 1 , 7 , 15 , 22 , 28 , 32 , 34 ) , HeLa S3 (cervical) ( 27 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 9 ) , HMLER ('stem, breast cancer') ( 9 ) , HOP62 (pulmonary) ( 17 ) , HUES-9 ('stem, embryonic') ( 21 ) , Jurkat (T lymphocyte) ( 14 , 31 , 35 , 36 ) , K562 (erythroid) ( 15 , 28 , 33 ) , KG-1 (myeloid) ( 20 ) , LCLC-103H (pulmonary) ( 17 ) , liver ( 11 ) , LOU-NH91 (squamous) ( 17 ) , MCF-7 (breast cell) ( 4 , 17 ) , MDA-MB-231 (breast cell) ( 17 ) , MDA-MB-468 (breast cell) ( 17 ) , MV4-11 (macrophage) ( 29 ) , NCEB-1 (B lymphocyte) ( 10 ) , NCI-H1395 (pulmonary) ( 17 ) , NCI-H1568 (pulmonary) ( 17 ) , NCI-H157 (pulmonary) ( 17 ) , NCI-H1648 (pulmonary) ( 17 ) , NCI-H1666 (pulmonary) ( 17 ) , NCI-H2030 (pulmonary) ( 17 ) , NCI-H2172 (pulmonary) ( 17 ) , NCI-H322 (pulmonary) ( 17 ) , NCI-H460 (pulmonary) ( 17 ) , NCI-H520 (squamous) ( 17 ) , NCI-H647 (pulmonary) ( 17 ) , ovary ( 8 ) , PC9 (pulmonary) ( 6 , 17 ) , PC9-IR (pulmonary) ( 6 ) , Raji (B lymphocyte) ( 10 ) , RAMOS (B lymphocyte) ( 10 ) , REC-1 (B lymphocyte) ( 10 ) , SKBr3 (breast cell) ( 16 ) , SU-DHL-4 (B lymphocyte) ( 10 ) , WM239A (melanocyte) ( 5 )

Upstream Regulation
Treatments:
EGF ( 1 ) , ischemia ( 8 ) , metastatic potential ( 23 ) , nocodazole ( 27 ) , SB202190 ( 28 ) , U0126 ( 28 )

References 

1

Huang H, et al. (2016) Simultaneous Enrichment of Cysteine-containing Peptides and Phosphopeptides Using a Cysteine-specific Phosphonate Adaptable Tag (CysPAT) in Combination with titanium dioxide (TiO2) Chromatography. Mol Cell Proteomics 15, 3282-3296
27281782   Curated Info

2

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

3

Giguère SS, et al. (2016) The Proteomic Profile of Deleted in Breast Cancer 1 (DBC1) Interactions Points to a Multifaceted Regulation of Gene Expression. Mol Cell Proteomics 15, 791-809
26657080   Curated Info

4

Carrier M, et al. (2016) Phosphoproteome and Transcriptome of RA-Responsive and RA-Resistant Breast Cancer Cell Lines. PLoS One 11, e0157290
27362937   Curated Info

5

Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615
25850435   Curated Info

6

Tsai CF, et al. (2015) Large-scale determination of absolute phosphorylation stoichiometries in human cells by motif-targeting quantitative proteomics. Nat Commun 6, 6622
25814448   Curated Info

7

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

8

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

9

Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90
24782546   Curated Info

10

Rolland D, et al. (2014) Global phosphoproteomic profiling reveals distinct signatures in B-cell non-Hodgkin lymphomas. Am J Pathol 184, 1331-42
24667141   Curated Info

11

Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62
24275569   Curated Info

12

Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96
23911959   Curated Info

13

Kim JY, et al. (2013) Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. Proc Natl Acad Sci U S A 110, 12414-9
23836654   Curated Info

14

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

15

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

16

Imami K, et al. (2012) Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways. Mol Cell Proteomics 11, 1741-57
22964224   Curated Info

17

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

18

Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70
22496350   Curated Info

19

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

20

Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56
22115753   Curated Info

21

Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3
21406692   Curated Info

22

Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5
21712546   Curated Info

23

Wang YT, et al. (2010) An informatics-assisted label-free quantitation strategy that depicts phosphoproteomic profiles in lung cancer cell invasion. J Proteome Res 9, 5582-97
20815410   Curated Info

24

Christensen GL, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9, 1540-53
20363803   Curated Info

25

Bennetzen MV, et al. (2010) Site-specific phosphorylation dynamics of the nuclear proteome during the DNA damage response. Mol Cell Proteomics 9, 1314-23
20164059   Curated Info

26

Schreiber TB, et al. (2010) An integrated phosphoproteomics work flow reveals extensive network regulation in early lysophosphatidic acid signaling. Mol Cell Proteomics 9, 1047-62
20071362   Curated Info

27

Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3
20068231   Curated Info

28

Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808
19651622   Curated Info

29

Oppermann FS, et al. (2009) Large-scale proteomics analysis of the human kinome. Mol Cell Proteomics 8, 1751-64
19369195   Curated Info

30

Gauci S, et al. (2009) Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach. Anal Chem 81, 4493-501
19413330   Curated Info

31

Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46
19690332   Curated Info

32

Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7
18669648   Curated Info

33

Stokes M (2008) CST Curation Set: 4388; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

34

Ruse CI, et al. (2008) Motif-specific sampling of phosphoproteomes. J Proteome Res 7, 2140-50
18452278   Curated Info

35

Stokes M (2008) CST Curation Set: 3881; Year: 2008; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

36

Stokes M (2008) CST Curation Set: 3882; Year: 2008; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info